AI Robotics in Medicine

Healthcare innovation is scaling up—from Cohen Orthopedic’s peer-voted 2026 robotics award and initial infrastructure work slated for its 47-acre Great Seal campus, to Tempus AI partnering on one of the largest angiosarcoma molecular datasets.

That precision push meets real-world risk: Healthline flags how common drugs (SSRIs, TCAs, GLP-1s, antipsychotics, beta-blockers, ACE inhibitors, diuretics) raise heat-illness odds amid record temperatures.

Watch the 600+ full-time and 100+ seasonal jobs and 2026 groundbreaking, and whether Tempus’s collaboration converts to fundamentals given 7. 9x sales vs 4.

7x peers and a price below a widely followed $65. 90 fair value.

Tracking: Medicine Robotics · AI Medicine · AI Healthcare

Geography: United States, European Union, United Kingdom, Canada, Israel, China, Japan, South Korea, India, Singapore, Boston, San Francisco Bay Area, New York City, London, Cambridge (UK), Toronto, Tel Aviv, Beijing, Shanghai, Shenzhen, Tokyo, Seoul, Bengaluru, Berlin, Paris, Stockholm, Houston (Texas Medical Center), Baltimore, Cleveland, Rochester (MN)

1. Cohen Orthopedic Wins 2026 Robotics Award, Advances Great Seal Campus

Cohen Orthopedic was named the 2026 Surgical Robotics Industry Awards Outstanding Healthcare Provider, a peer-voted honor spotlighting robotic-assisted surgery’s precision, personalization, and recovery benefits.

Dr. Brian Cohen called it the practice’s second time receiving the award and credited the team. The practice is an early adopter of Stryker’s MAKO robotic-arm system; industry coverage cited Dr. Cohen with 3,000+ MAKO-assisted hip, knee, and revision cases.

At the same time, Cohen Orthopedic is advancing the Great Seal Medical Center, a multi-building campus on roughly 47 acres off River Road across from Adena Regional Medical Center.

Initial infrastructure work is slated to begin in early July, with a public groundbreaking expected later in 2026. Local reporting estimates 600+ full-time and 100+ seasonal jobs, with plans for a medical office building and an ambulatory surgery center.

Key facts:

- Named 2026 Surgical Robotics Industry Awards Outstanding Healthcare Provider.

- The award is peer-voted, highlighting robotic-assisted surgery improving outcomes.

- Dr. Brian Cohen reports winning the award a second time.

- Dr. Cohen has performed 3,000+ MAKO-assisted hip, knee, and revision procedures.

- Great Seal campus planned on roughly 47 acres off River Road.

Why it matters: For southern Ohio patients, a robotics-forward ambulatory surgery center can expand access to advanced joint procedures closer to home and support faster recovery pathways.

For the market, a high-volume MAKO user building capacity across from a regional hospital underscores the shift of orthopedic volume to outpatient settings. It also signals continued diffusion of robotic-assisted surgery beyond major academic centers.

Watch for the July infrastructure start and the later-2026 groundbreaking to gauge timeline and hiring ramp.

Hoodline

2. Healthline flags heat risks tied to antidepressants, GLP-1s, beta-blockers

With heatwaves becoming more common — and July 2024 the hottest month ever recorded — Healthline details medications that heighten heat-related illness risk.

Antidepressants (SSRIs, TCAs), GLP-1s, antipsychotics, beta-blockers, ACE inhibitors, and diuretics can drive dehydration, disrupt sweating, impair thermoregulation, or blunt thirst and heat perception.

Healthline cites 2022 research showing antidepressants can push core temperature to 106°F, elevating heat exhaustion and heatstroke risk.

The American Heart Association notes beta-blockers can exaggerate the body’s heat response; lithium can tip into dehydration-induced toxicity.

Family physician David Cutler warns that medications reducing sweating and diuretics are especially risky in hot weather, advising patients to keep cool, hydrate, make a heat plan, and consult clinicians before changing prescriptions.

Key facts:

- July 2024 was the hottest month ever recorded.

- Antidepressants, GLP-1s, beta-blockers increase heat illness risk.

- 2022 research: antidepressants can raise core temperature to 106°F.

- AHA: beta-blockers can exaggerate the body’s heat response.

- ACE inhibitors may suppress thirst and raise heat illness risk.

Why it matters: Heat advisories now have direct medication-safety implications. Health systems, payers, and pharmacies can target proactive outreach to patients on these drug classes during heatwaves, emphasizing hydration, cooling strategies, and when to seek care.

Clinicians can embed prompts in EHRs or CDS to review heat risks and counsel patients, especially those on diuretics, beta-blockers, ACE inhibitors, antidepressants, antipsychotics, GLP-1s, or lithium.

Telemedicine triage should screen for these medications, and remote monitoring programs for cardiovascular patients may need tighter thresholds in extreme heat.

Healthline

3. Tempus AI collaborates on large angiosarcoma dataset; stock deemed undervalued

Tempus AI announced a collaboration with Angiosarcoma Awareness, Inc. to support work on one of the largest molecular datasets for this rare cancer, tying its AI platform more directly to high-impact research.

The move has drawn fresh investor attention to Tempus’s data assets and arrives alongside recent research collaborations and validation work on its ECG-AF software. Amid this momentum, shares trade at $60.

27 after a 30-day gain of 29. 81% and a 90-day rise of 27.

42%, though year-to-date returns are down 3. 35% and the 1-year total shareholder return is down 1.

15%. A widely followed narrative pegs fair value at $65.

90—above the current price—while highlighting Tempus as a healthcare data platform where diagnostics, genomics, clinical data, and AI applications reinforce each other. Yet the stock trades at 7.

9x sales versus 4. 7x peers and 4x the broader U.S. life sciences industry, underscoring premium expectations and execution risk.

Key facts:

- Collaboration announced with Angiosarcoma Awareness, Inc.

- Focus on one of the largest angiosarcoma molecular datasets.

- Stock price cited at $60.27.

- 30‑day return 29.81%; 90‑day return 27.42%.

- Year‑to‑date return down 3.35%; 1‑year TSR down 1.15%.

Why it matters: Rare-cancer datasets are hard to assemble; aligning with a patient group on a large molecular resource can deepen Tempus’s data flywheel and make its platform more attractive to researchers and partners.

That supports the “underpriced platform” narrative, but a 7. 9x sales multiple narrows the margin for error.

Execution now needs to show sustained profitability progress and real-world adoption of Tempus’s tools. Watch for concrete outputs from the angiosarcoma collaboration and continued ECG-AF validation milestones as near-term tests of the growth thesis.

Simplywall